- First biosimilar insulin to receive CHMP positive opinion in the EU INDIANAPOLIS and INGELHEIM, Germany, June 27, 2014 / PRNewswire / Asianet-Pakistan — The Committee for Medicinal Products for Human Use (CHMP) today issued a positive opinion recommending approval for the investigational compound LY2963016, a new insulin glargine product, for the treatment of type […]
The post CHMP Recommends Lilly and Boehringer Ingelheim’s New Insulin Glargine Product for Approval in the European Union appeared first on Business News Pakistan.
Read More »